PRECISION BIOSCIENCES INC 8-K

What Happened

• Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8‑K on January 12, 2026 reporting a preliminary, unaudited estimate of approximately $137 million in cash, cash equivalents and restricted cash as of December 31, 2025. The company said its independent audit is ongoing and the amount could change.
• The company also disclosed clinical program updates: additional biopsy data from the ELIMINATE‑B trial (PBGENE‑HBV) is expected in the first half of 2026, and pending IND clearance the FUNCTION‑DMD Phase 1/2 trial is expected to dose its first patient in late Q1 or early Q2 2026, with initial multi‑patient data expected by year‑end 2026. A press release was furnished as Exhibit 99.1 and the corporate presentation was updated on the company’s investor website.

Key Details

• Estimated cash, cash equivalents and restricted cash as of 12/31/2025: ~$137 million (unaudited, preliminary).
• Company expects existing cash, potential near‑term licensee consideration, fiscal/operating discipline, and its at‑the‑market (ATM) facility could extend its cash runway through 2028.
• ELIMINATE‑B (PBGENE‑HBV): additional biopsy data expected H1 2026; completing dosing Cohorts 3–5 and selecting optimal dosing to attempt stopping nucleos(t)ide analog therapy and start Part 2 expansion.
• FUNCTION‑DMD: pending IND clearance, first patient dosing targeted late‑Q1/early‑Q2 2026; initial multi‑patient data expected by year‑end 2026.

Why It Matters

• The cash estimate gives investors an interim view of Precision BioSciences’ liquidity before audited results are released; management signals funding runway may last through 2028 assuming expected receipts and financing options.
• Clinical timelines for PBGENE‑HBV and FUNCTION‑DMD set near‑term catalysts (biopsy data and initial dosing/data milestones) that investors commonly watch for biotech valuation and partnership potential.
• All timelines and financial expectations are forward‑looking and subject to audit adjustments, regulatory reviews (e.g., IND clearance), trial outcomes, and other risks described in the company’s SEC filings.